Clemedi is a Swiss company based in Zurich that specializes in developing diagnostics for infectious diseases. Through the combination of DNA sequencing and artificial intelligence, Clemedi offers innovative solutions to address the current misuse and overuse of antibiotics. Their product portfolio includes reagents and software for use in laboratories, with a focus on providing targeted diagnostics.

One of Clemedi's standout products is their test for tuberculosis, which sets them apart from others on the market. By analyzing more resistance markers and utilizing advanced algorithms, they can accurately predict antibiotic susceptibility and bacterial culture in a much shorter time frame. Clemedi's process involves extracting DNA from patient samples, amplifying regions associated with drug resistance, sequencing amplicons using cutting-edge technology, and analyzing the sequencing data with artificial intelligence to generate a comprehensive report.

Clemedi's vision is to combat the growing threat of antimicrobial resistance by ensuring antibiotics are only prescribed when they are effective. By reducing antibiotic consumption and the spread of resistance, they aim to make a positive impact in healthcare. In addition to tuberculosis, Clemedi is also researching and developing assays for sexually transmitted infections and hospital-acquired infections.

For laboratories, distributors, and investors interested in Clemedi's products and services, they offer various opportunities for collaboration. Whether it's purchasing their products or partnering in their mission to revolutionize infectious disease diagnostics, Clemedi welcomes engagement from interested parties. With their cutting-edge platform and aim to expand into new product lines, Clemedi is actively seeking investment to fuel their growth and market entry.

Clemedi: Ending antibiotic misuse through innovative diagnostics for infectious diseases